Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COLLNASDAQ:ETNBNASDAQ:LFCRNASDAQ:MLYS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$27.010.0%$28.74$23.23▼$42.29$867.89M0.76444,671 shs227,917 shsETNB89bio$6.06+2.9%$8.04$4.16▼$11.84$884.66M1.251.31 million shs1.02 million shsLFCRLifecore Biomedical$6.41+1.1%$6.17$3.68▼$7.99$237.33M0.8229,058 shs193,286 shsMLYSMineralys Therapeutics$13.35-1.1%$12.59$8.24▼$18.38$866.10M-0.39416,447 shs382,306 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical0.00%+2.70%-9.51%-19.01%-23.81%ETNB89bio0.00%+9.58%-31.06%-3.96%-33.84%LFCRLifecore Biomedical0.00%+10.14%-3.61%-1.08%-1.84%MLYSMineralys Therapeutics0.00%-0.37%-20.30%+44.48%+11.25%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOLLCollegium Pharmaceutical4.1822 of 5 stars3.42.00.03.03.40.82.5ETNB89bio2.7809 of 5 stars4.51.00.00.02.61.70.6LFCRLifecore Biomedical1.1381 of 5 stars2.20.00.00.02.33.30.6MLYSMineralys Therapeutics2.5422 of 5 stars3.51.00.00.02.55.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOLLCollegium Pharmaceutical 2.80Moderate Buy$43.6061.42% UpsideETNB89bio 2.90Moderate Buy$27.56354.71% UpsideLFCRLifecore Biomedical 2.33Hold$8.0024.80% UpsideMLYSMineralys Therapeutics 3.00Buy$33.00147.19% UpsideCurrent Analyst Ratings BreakdownLatest LFCR, MLYS, ETNB, and COLL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2025COLLCollegium PharmaceuticalNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.00 ➝ $46.004/8/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)4/2/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$30.00 ➝ $42.003/24/2025COLLCollegium PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.003/22/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)3/14/2025ETNB89bioThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$11.003/13/2025ETNB89bioCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$25.003/10/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/7/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)2/28/2025ETNB89bioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $21.002/24/2025MLYSMineralys TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 4/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOLLCollegium Pharmaceutical$631.45M1.37$9.79 per share2.76$5.99 per share4.51ETNB89bioN/AN/AN/AN/A$5.75 per shareN/ALFCRLifecore Biomedical$130.86M1.81N/AN/A$0.37 per share17.32MLYSMineralys TherapeuticsN/AN/AN/AN/A$3.84 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOLLCollegium Pharmaceutical$48.15M$1.8611.644.49N/A14.78%104.67%18.38%5/8/2025 (Estimated)ETNB89bio-$142.19M-$3.43N/AN/AN/AN/A-59.58%-52.21%5/8/2025 (Estimated)LFCRLifecore Biomedical$12.01M-$1.45N/AN/AN/A-12.52%-315.23%-12.74%N/AMLYSMineralys Therapeutics-$177.81M-$3.64N/AN/AN/AN/A-67.97%-62.40%5/8/2025 (Estimated)Latest LFCR, MLYS, ETNB, and COLL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025COLLCollegium Pharmaceutical$1.50N/AN/AN/A$174.96 millionN/A5/8/2025Q1 2025ETNB89bio-$0.50N/AN/AN/AN/AN/A5/8/2025Q1 2025MLYSMineralys Therapeutics-$1.02N/AN/AN/AN/AN/A4/3/2025Q3 2025LFCRLifecore Biomedical-$0.14-$0.19-$0.05-$0.47$33.23 million$35.15 million3/6/2025Q4 2024ETNB89bio-$0.60-$1.02-$0.42-$1.02N/AN/A2/27/2025Q4 2024COLLCollegium Pharmaceutical$1.54$1.63+$0.09$0.36$179.68 million$181.95 million2/12/2025Q4 2024MLYSMineralys Therapeutics-$1.00-$0.98+$0.02-$0.98N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOLLCollegium PharmaceuticalN/AN/AN/AN/AN/AETNB89bioN/AN/AN/AN/AN/ALFCRLifecore BiomedicalN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOLLCollegium Pharmaceutical3.430.970.88ETNB89bio0.0911.6611.66LFCRLifecore Biomedical9.212.321.21MLYSMineralys TherapeuticsN/A14.0214.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOLLCollegium PharmaceuticalN/AETNB89bioN/ALFCRLifecore Biomedical83.36%MLYSMineralys Therapeutics84.46%Insider OwnershipCompanyInsider OwnershipCOLLCollegium Pharmaceutical2.51%ETNB89bio2.80%LFCRLifecore Biomedical32.20%MLYSMineralys Therapeutics33.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOLLCollegium Pharmaceutical21032.13 million30.97 millionOptionableETNB89bio40145.98 million103.15 millionOptionableLFCRLifecore Biomedical69037.03 million26.58 millionOptionableMLYSMineralys Therapeutics2864.88 million33.27 millionOptionableLFCR, MLYS, ETNB, and COLL HeadlinesRecent News About These CompaniesVanguard Group Inc. Grows Stock Holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)April 19 at 3:08 AM | marketbeat.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Sees Large Growth in Short InterestApril 18 at 2:24 PM | marketbeat.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Sells $129,729.42 in StockApril 17 at 11:56 PM | marketbeat.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Insider Sells $165,147.98 in StockApril 17 at 11:56 PM | marketbeat.comInsider Selling: Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CEO Sells 15,319 Shares of StockApril 17 at 8:47 PM | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Shares Gap Up - Still a Buy?April 16 at 10:46 AM | marketbeat.comWellington Management Group LLP Boosts Stock Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)April 15, 2025 | marketbeat.comInstitutional investors must be pleased after a 8.1% gain last week that adds to Mineralys Therapeutics, Inc.'s (NASDAQ:MLYS) one-year returnsApril 12, 2025 | finance.yahoo.comMineralys Therapeutics (NASDAQ:MLYS) Trading Down 5.6% - Should You Sell?April 11, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Shares Gap Down - Time to Sell?April 10, 2025 | marketbeat.comADAR1 Capital Management LLC Increases Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)April 9, 2025 | marketbeat.comHC Wainwright Analysts Boost Earnings Estimates for MLYSApril 8, 2025 | marketbeat.comPrudential Financial Inc. Acquires 58,000 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS)April 7, 2025 | marketbeat.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Insider David Malcom Rodman Sells 55,771 SharesApril 5, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Sees Unusually-High Trading Volume After Analyst UpgradeApril 4, 2025 | marketbeat.comHC Wainwright Issues Positive Forecast for Mineralys Therapeutics (NASDAQ:MLYS) Stock PriceApril 4, 2025 | marketbeat.comInsider Selling: Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Insider Sells 55,771 Shares of StockApril 4, 2025 | insidertrades.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Sold by American Century Companies Inc.April 4, 2025 | marketbeat.comMineralys Therapeutics price target raised to $42 from $30 at H.C. WainwrightApril 2, 2025 | markets.businessinsider.comMineralys Therapeutics (NASDAQ:MLYS) Shares Gap Up - Here's What HappenedApril 2, 2025 | marketbeat.comBuy Rating Affirmed for Lorundrostat Amid Positive Trial Results and Market PotentialApril 2, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLFCR, MLYS, ETNB, and COLL Company DescriptionsCollegium Pharmaceutical NASDAQ:COLL$27.01 -0.01 (-0.04%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$27.02 +0.00 (+0.02%) As of 04/17/2025 04:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.89bio NASDAQ:ETNB$6.06 +0.17 (+2.89%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$6.06 +0.01 (+0.08%) As of 04/17/2025 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Lifecore Biomedical NASDAQ:LFCR$6.41 +0.07 (+1.10%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$6.40 0.00 (-0.08%) As of 04/17/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.Mineralys Therapeutics NASDAQ:MLYS$13.35 -0.15 (-1.11%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$13.33 -0.02 (-0.15%) As of 04/17/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Aviation Unveils NYC Network Ahead of Key Earnings Report Joby Aviation Stock Presents an Opportunity in the Turbulence Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally Tariff-Resistant Kinder Morgan Is a Good Buy in 2025 Rocket Lab's Growth Potential Gains Altitude on Defense News Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk 3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks Tariff-Resistant Abbott Laboratories on Track for New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
